Cancer BiologybioRxivPreprint
A tumor-cell MHC-II program is associated with checkpoint-blockade outcomes across stages of bladder cancer
Joaquim Bellmunt B, Yingtian Xie, Miguel Gómez Muñoz…·Henry W. Long
This study identifies a tumor-cell MHC-II program linked to immunotherapy outcomes in bladder cancer across different stages and treatment settings.